# of Displayed Technologies: 8 / 8

Applied Category Filter (Click To Remove): Oncology


Categories

Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types
The Technology Dr. Margaret Liu and colleagues have developed a dual-payload antibody-drug conjugate (DualADC) for chemo-immunotherapy utilizing a new humanized antibody that targets CD276, a surface receptor that is overexpressed in Triple-negative Breast Cancers (TNBCs), lung cancer (including non…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need: Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
  • Licensing Officer: Schworer, Adam

A novel mouse model of spontaneous chronic lymphocytic leukemia
TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.
The Need Chronic lymphocytic leukemia (CLL) accounts for one quarter of new cases of leukemia. CLL is the most prevalent adult leukemia in Western countries and is characterized by a mature B-cell phenotype. Given the burden of this disease, a large pipeline of drugs for treatment are in progress…
  • College: College of Medicine (COM)
  • Inventors: Lapalombella, Rosa; Blachly, James; Byrd, John
  • Licensing Officer: Schworer, Adam

RNA Sequencing Assay to Detect Gene Fusion Mutations that Occur in Multiple Cancer Types
TS-038065 — OSU­-SpARKFUSE is an RNA sequencing assay that detects known and novel gene fusion mutations in multiple cancer types.
Chromosomal rearrangements, leading to the juxtaposition of two unrelated genes and thus creating a chimeric mRNA transcript and protein ("gene fusions"), are important drivers of abnormal cell growth in cancers. Although gene fusions have a well-established role in hematologic malignanc…
  • College: College of Medicine (COM)
  • Inventors: Roychowdhury, Sameek
  • Licensing Officer: Schworer, Adam

Targeted molecules for the treatment of cancer
TS-038027 — Novel dihdroorotate dehydrogenase (DHODH) small-molecule inhibitors for the treatment of Acute Myeloid Leukemia, Multiple Myeloma, & Graft vs. Host Disease / Leukemia.
DHODH is a rate-limiting enzyme in de novo pyrimidine synthesis. Rapidly dividing cancer cells are therefore sensitive to blockade of this pathway. New research has shown DHODH inhibition can induce differentiation in acute myeloid leukemia (AML) cell lines, translating to increased survival in an…
  • College: College of Medicine (COM)
  • Inventors: Byrd, John; Abdulrahim, Mouad; Elgamal, Ola; Goodwin, Thomas; Hertlein, Erin; Ravikumar, Pratheepa; Shah, Dimple
  • Licensing Officer: Schworer, Adam

Six Degrees-of-Freedom Quality Assurance Phantom for Radiation Therapy Linear Accelerators
TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.
6DoF treatment tables allow for 2 additional degrees (pitch and roll) compared to traditional 4DoF (vertical, lateral, longitudinal, and yaw) when correcting for patient setup during image-guidance prior to treatment delivery. These tables allow for more accurate patient treatments and could poten…
  • College: OSU Wexner Medical Center
  • Inventors: Woods, Kyle; Ayan, Ahmet; Gupta, Nilendu; Woollard, Jeffrey
  • Licensing Officer: Schworer, Adam

miRNA-based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy
TS-037521 — A method to use MiRNA to predict the likelihood of biochemical failure after radiation surgery.
The Need Prostate cancer is one of the most common cancers worldwide, but current treatments can sometimes lead to complications. For example, radical prostatectomy is widely used for men in the early stages of prostate cancer, but long-term data shows that 30-40% of these patients experience bioch…
  • College: College of Medicine (COM)
  • Inventors: Chakravarti, Arnab; Bell, Erica
  • Licensing Officer: Schworer, Adam

miR-3151 and BAALC as a Target for Drug Therapy
TS-014895 — Identified gene target for treatment of human acute leukemia, brain tumors and melanoma
Treatment failure is one of the leading causes of death in patients with human acute leukemia, yet the cause of treatment failure is still largely unknown. Overexpression of the RNA gene miR-3151 and its host gene, Brain and Acute Leukemia, Cytplasmic (BAALC), is a sign of an ineffective treatment…
  • College: College of Medicine (COM)
  • Inventors: de la Chapelle, Albert; Eisfeld, Ann-Kathrin; Tanner, Stephan
  • Licensing Officer: Schworer, Adam

Loading icon